TICKERNERD
Menu
ARWRARWRHealthcare · Biotechnology

ARWR Stock Forecast: Arrowhead Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$62
−1.30% on the day

The 14 Wall Street analysts covering Arrowhead Pharmaceuticals, Inc. hold a median 12-month price target of $104 — +69.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 5 Oct 2026 — in the upper half.

Market cap
$9.1B
Ticker Nerd rank
55 / 100
Median analyst target
$104
Analysts covering
14
Revenue$75.3M+171.0% y/y
Operating income−$170.1M
Net income−$178.9M
Free cash flow−$181.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.1%
1M
−28.7%
YTD
−7.3%
1Y
+64.1%
From 52W high
−31.3%
From 52W low
+73.8%
$35
$90
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ARWR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Arrowhead Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Oct 2026
55 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
93
Value
90
Momentum
79
Accruals
74
Volatility
47
Revisions
39
Growth
37
Size
17
Issuance
12

Quality (93): The business earns solid, repeatable profits on what it owns.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ARWR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARWR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100$120$140Jan 26Apr 26Jul 26Oct 26ARWRHigh $126Median $104Low $74

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
13 Buy1 Hold0 Sell
Low $74Median $104High $126

The green dot is the last close — the median target sits +69.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
24 Sept 2026Goldman SachsReinstatesNeutral$74
8 Sept 2026CitigroupInitiatesBuy$108
8 Sept 2026CitigroupInitiatesBuy—
1 Sept 2026HC Wainwright & Co.ReiteratesBuy—
1 Sept 2026HC Wainwright & Co.ReiteratesBuy$120
31 Aug 2026Chardan CapitalMaintainsBuy$115
31 Aug 2026Chardan CapitalMaintainsBuy—
31 Aug 2026RBC CapitalReiteratesOutperform$100
31 Aug 2026RBC CapitalReiteratesOutperform—
6 Aug 2026HC Wainwright & Co.MaintainsBuy—
6 Aug 2026HC Wainwright & Co.MaintainsBuy$115 → $120
30 July 2026B. Riley SecuritiesMaintainsBuy—
30 July 2026B. Riley SecuritiesMaintainsBuy$101 → $123
27 July 2026HC Wainwright & Co.MaintainsBuy$100 → $115
27 July 2026HC Wainwright & Co.MaintainsBuy—
23 July 2026Morgan StanleyMaintainsOverweight—
23 July 2026Morgan StanleyMaintainsOverweight$100 → $120
23 July 2026Piper SandlerReiteratesOverweight$110 → $126
23 July 2026Piper SandlerReiteratesOverweight—
22 July 2026Chardan CapitalMaintainsBuy$90 → $115

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ARWR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ARWR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, Arrowhead Pharmaceuticals, Inc. returned +64.1% against +17.3% for the S&P 500, dividends included.

ARWR vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26ARWRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ARWR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
6
Fundamentals

Arrowhead Pharmaceuticals, Inc. (ARWR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
47.1×

Cheaper than 16% of US stocks

Price / sales
13.5×

Cheaper than 12% of US stocks

Price / book
19.5×

Cheaper than 5% of US stocks

EV / EBITDA
−44.1×

Cheaper than 94% of US stocks

Growth & margins
Revenue growth (YoY)
171.0%

Higher than 95% of US stocks

Earnings growth (YoY)
171.0%

Higher than 89% of US stocks

Gross margin
—
Operating margin
−226.0%

Higher than 10% of US stocks

Net margin
−47.8%

Higher than 10% of US stocks

Returns & dividend
Return on equity
−55.2%

Higher than 20% of US stocks

Return on assets
−8.1%

Higher than 28% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Arrowhead Pharmaceuticals, Inc. (ARWR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Arrowhead Pharmaceuticals, Inc. has a market value of $9.1B and an enterprise value of $8.8B.

  • Revenue in the twelve months to 30 June 2026: $669.5M. The latest quarter grew 171.0% year on year.

  • Net income over the same four quarters: −$272.1M, a −40.6% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$75.1M.

  • Shares outstanding: 141.1M.

  • Trailing P/E: 47.1×; forward P/E: −13.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Arrowhead Pharmaceuticals, Inc. employs 711 people — $942K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

ARWR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ARWRArrowhead Pharmaceuticals, Inc.$9.1B
55
CYTKCytokinetics, Inc.$8.7B
49
CAICaris Life Sciences, Inc.$8.6B
35
TGTXTG Therapeutics, Inc.$8.6B
68
PTGXProtagonist Therapeutics, Inc.$9.0B
97
AXSMAxsome Therapeutics, Inc.$9.1B
70
KYMRKymera Therapeutics, Inc.$9.1B
72

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Arrowhead Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ARWR news & analysis

Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher

Seeking Alpha · 3 Oct 2026positive

Arrowhead Pharmaceuticals is positioned to challenge Ionis in severe hypertriglyceridemia with plozasiran, having used a $215 million priority review voucher to enable a faster launch. Phase III data from SHASTA-3 and SHASTA-4 showed 79-81% median triglyceride reductions with favorable safety on quarterly dosing, while post-voucher liquidity of about $1.35 billion supports operations into early 2028.

Why it matters — The analysis highlights plozasiran's strong Phase III efficacy and safety profile alongside a fast-tracked launch path, giving Arrowhead watchers a clearer picture of the company's competitive positioning and financial runway.

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Business Wire · 29 Sept 2026neutral

Arrowhead Pharmaceuticals announced it will host an R&D webinar on October 14, 2026, focusing on its investigational therapy ARO-MAPT and its central nervous system pipeline. The webinar, featuring a presentation by UCSF professor Adam Boxer, will include interim clinical data from a Phase 1/2a study of ARO-MAPT for Alzheimer's disease and other tauopathies.

Why it matters — ARWR watchers would care because the webinar provides an early look at interim clinical data for ARO-MAPT, a key candidate in Arrowhead's CNS pipeline targeting Alzheimer's disease.

Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress

MarketBeat · 19 Sept 2026positive

Arrowhead Pharmaceuticals executives presented early clinical data for its RNA interference dimer program, highlighted progress in the launch of plozasiran, and discussed plans for central nervous system and metabolic disease candidates at the Morgan Stanley Global Healthcare Conference. CEO Chris Anzalone said the ARO-DIMER-PA candidate represents the first demonstration of knockdown of two genes with a single RNAi molecule.

Why it matters — A shareholder would care because the early dual-target RNAi data and plozasiran launch progress could signal advancement of Arrowhead's pipeline and commercial trajectory.

Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands

MarketBeat · 18 Sept 2026positive

Arrowhead Pharmaceuticals is expanding its commercial and clinical presence in RNA interference therapies, following the launch of its triglyceride-lowering treatment REDEMPLO and advancing multiple pipeline programs across cardiometabolic disease, obesity and central nervous system disorders.

Why it matters — A watcher of Arrowhead would care because the company is broadening its RNAi platform beyond its recent commercial launch into several new therapeutic areas, potentially adding to its pipeline value.

FAQ

Frequently asked questions about ARWR stock

What is the ARWR stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Arrowhead Pharmaceuticals, Inc. have a median 12-month price target of $104, with estimates ranging from $74 to $126. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ARWR stock a buy right now?

Of the 14 analysts covering Arrowhead Pharmaceuticals, Inc., 13 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arrowhead Pharmaceuticals, Inc. 55 out of 100 across roughly 4,600 US stocks as at 5 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARWR?

As at 5 Oct 2026, Arrowhead Pharmaceuticals, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (93 of 100).

Will ARWR stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +69.0% from the last close, and Ticker Nerd's factor model ranks Arrowhead Pharmaceuticals, Inc. 55 out of 100 as at 5 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ARWR stock forecast for 2030?

No analyst covering Arrowhead Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARWR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $74 to $126 over the next 12 months.

How has ARWR stock performed over the past year?

Arrowhead Pharmaceuticals, Inc. returned +64.1% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Arrowhead Pharmaceuticals, Inc. do?

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company that develops medicines for intractable diseases using RNA interference, a gene-silencing approach designed to reduce the production of disease-causing proteins.

What is the latest news on ARWR?

The most recent item we track (Seeking Alpha, 3 Oct 2026): "Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher". Arrowhead Pharmaceuticals is positioned to challenge Ionis in severe hypertriglyceridemia with plozasiran, having used a $215 million priority review voucher to enable a faster launch. Phase III data from SHASTA-3 and SHASTA-4 showed 79-81% median triglyceride reductions with favorable safety on quarterly dosing, while post-voucher liquidity of about $1.35 billion supports operations into early 2028.

Company

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company that develops medicines for intractable diseases using RNA interference, a gene-silencing approach designed to reduce the production of disease-causing proteins. Arrowhead Pharmaceuticals focuses on therapeutic areas including cardiometabolic, liver, pulmonary, neuromuscular, complement-mediated, and central nervous system disorders. Its portfolio includes both commercial and clinical-stage programs built around its targeted RNAi platform, which is designed for tissue-specific delivery and precise gene suppression. The company works across product development, clinical research, and commercialization, with a pipeline that includes multiple investigational therapies aimed at genetically driven diseases. Arrowhead Pharmaceuticals serves the broader healthcare market by advancing treatments for complex conditions with limited options, positioning itself as a specialized player in RNA-based drug development.

CEO Dr. Christopher R. Anzalone Ph.D. · 711 employees · United States · https://arrowheadpharma.com